Michael B Gatch
Overview
Explore the profile of Michael B Gatch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
899
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munir D, Shetty R, Gatch M, Sumien N, Hill R, Priddy J, et al.
Behav Pharmacol
. 2024 Dec;
36(2-3):107-114.
PMID: 39642035
Despite the efforts of the Drug Enforcement Administration to safeguard the public from hazardous analogs of synthetic hallucinogens, these compounds have increasingly been observed in the illicit drug market. Four...
2.
Hill R, Shetty R, Sumien N, Forster M, Gatch M
Drug Alcohol Depend Rep
. 2023 Aug;
8:100182.
PMID: 37600151
Aims: Benzofurans are used recreationally, due their ability to cause psychostimulant and/or entactogenic effects, but unfortunately produce substantial adverse effects, including death. Three benzofurans 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB), 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-MAPB) and 6-(2-aminopropyl)...
3.
Shetty R, Hoch A, Sumien N, Forster M, Gatch M
J Psychopharmacol
. 2023 Feb;
37(5):520-528.
PMID: 36738095
Background: The underground market is constantly flooded with newer synthetic as alternatives to the older cathinones. Drug Enforcement Administration (DEA) has identified four cathinone compounds of particular concern: 3,4-methylenedioxy-alpha-pyrrolidinohexanophenone (3,4-MD-α-PHP),...
4.
Gatch M, Hoch A, Carbonaro T
ACS Pharmacol Transl Sci
. 2021 Apr;
4(2):467-471.
PMID: 33860176
Novel synthetic compounds have been available for decades as quasi-legal alternatives to controlled substances. The hallucinogen-like effects of eight novel substituted tryptamines were evaluated to determine their potential abuse liability....
5.
Gatch M, Tourigny A, Shetty R, Forster M
Behav Pharmacol
. 2021 Feb;
33(2&3):175-183.
PMID: 33595956
Newly emerging synthetic cannabinoid compounds continue to be found in the designer drug market. They are often targeted as a 'legal high' alternative to traditional cannabinoids via 'darknet' markets and...
6.
Gatch M, Shetty R, Sumien N, Forster M
Addict Biol
. 2020 Nov;
26(4):e12987.
PMID: 33155384
A new generation of novel cathinone compounds has been developed as stimulant substitutes to avoid drug control laws and detection of use by blood tests. Dipentylone, N-ethylhexedrone, 4-chloroethcathinone (4-CEC), and...
7.
Gatch M, Forster M
J Psychopharmacol
. 2020 Jun;
34(7):778-785.
PMID: 32536334
Background: Synthetic cathinone derivatives are used as alternatives both for stimulant drugs such as cocaine and methamphetamine and for club drugs such as 3,4-methylenedioxymethamphetamine (MDMA), but little is known about...
8.
Carbonaro T, Nguyen V, Forster M, Gatch M, Prokai L
Neuropharmacology
. 2020 Jun;
174:108152.
PMID: 32479814
Carisoprodol (Soma®) is a centrally-acting skeletal-muscle relaxant frequently prescribed for treatment of acute musculoskeletal conditions. Carisoprodol's mechanism of action is unclear and is often ascribed to that of its active...
9.
Gatch M, Dolan S, Forster M
Behav Pharmacol
. 2020 Jan;
31(4):378-384.
PMID: 31895060
Synthetic cathinone derivatives are commonly considered quasi-legal alternatives for stimulant drugs, such as cocaine and methamphetamine, but some derivatives are increasingly being detected in club drug formulations of Ecstasy or...
10.
Gatch M, Dolan S, Forster M
Drug Alcohol Depend
. 2019 Apr;
199:50-58.
PMID: 30986635
Background: The development of novel synthetic psychoactive substances continues to accelerate. There are little or no data on the pharmacological mechanisms, behavioral effects, or abuse liability of many of the...